9 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 4 Phase 3, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Active not recruiting 1, Not yet recruiting 1 |
| Phase 3 | 4 | Recruiting 3, Active not recruiting 1 |
| Not applicable | 3 | Recruiting 3 |
Follow OligoProgressive Metastatic Disease: new trials by email Literature Review of OligoProgressive Metastatic Disease trials Research Report on OligoProgressive Metastatic Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) Radiotherapy - Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease | Phase 2 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-09-01 | 2026-08-13 |
| Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy - Oligoprogression, Oligometastatic Disease | Not applicable | Recruiting | British Columbia Cancer Agency | 194 | 2025-12-04 | 2025-12-15 |
| Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) SBRT - OligoProgressive Metastatic Disease | Not applicable | Recruiting | Jules Bordet Institute | 48 | 2025-10-30 | 2026-02-02 |
| Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma Stereotactic Body Radiation Therapy (SBRT) - Metastatic Melanoma, OligoProgressive Metastatic Disease | Not applicable | Recruiting | University Health Network, Toronto | 52 | 2025-07-24 | 2026-03-05 |
| Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC radiotherapy, Systemic therapy (Continuation of current first-line systemic therapy), Systemic therapy (Early switch to second-line systemic therapy) - OligoProgressive Metastatic Disease, Hepatocellular Carcinoma (HCC) | Phase 3 | Recruiting | Shandong Cancer Hospital and Institute | 132 | 2025-07-21 | 2026-10-13 |
| Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer Stereotactic Body Radiation Therapy (SBRT), Systemic therapy - Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease | Phase 2 | Recruiting | University Health Network, Toronto | 75 | 2025-07-08 | 2026-07-07 |
| Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） Radiotherapy or Surgery, Standard Medical Therapy - OligoProgressive Metastatic Disease, Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Shanghai Chest Hospital | 97 | 2025-06-03 | 2025-07-22 |
| Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer IMSA101 - Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 15 | 2025-04-01 | 2025-11-12 |
| The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC) Metastasis directed radiotherapy - Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease | Phase 2 | Recruiting | University Medical Center Groningen | 35 | 2025-01-03 | 2025-06-26 |
| Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer Stereotactic Body Radiotherapy, second-line systemic therapy - Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 104 | 2024-09-01 | 2024-08-30 |
| A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP) Local Consolidation Therapy, Next-line Systemic Therapy - OligoProgressive Metastatic Disease | Phase 2 / Phase 3 | Recruiting | M.D. Anderson Cancer Center | 400 | 2024-06-06 | 2026-06-11 |
Carcinoma, Non-Small-Cell Lung (3) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Bites and Stings (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Neoplasms (8) · Neoplasms by Site (8) · Neoplasms by Histologic Type (4) · Bronchial Neoplasms (3) · Carcinoma (3) · Carcinoma, Bronchogenic (3) · Lung Diseases (3) · Lung Neoplasms (3) · Neoplasms, Glandular and Epithelial (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Adenocarcinoma (2) · Male Urogenital Diseases (2) · Neoplastic Processes (2)
Radiosurgery (3) · Radiotherapy (3) · Immunotherapy (1) · Surgical Procedures, Operative (1)
University Health Network, Toronto (3) · British Columbia Cancer Agency (1) · Jules Bordet Institute (1) · M.D. Anderson Cancer Center (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Chest Hospital (1) · University Medical Center Groningen (1) · University of Texas Southwestern Medical Center (1)
Canada (4) · China (3) · United States (2) · Belgium (1) · Netherlands (1)
Ethan Ludmir (1) · Fuming Qiu, PhD (1) · Jinbo Yue, Doctor (1) · Rachel Glicksman, MD (1)